Pharma Firm to Present Data from Omega-3 Drug Trial

April 20, 2011

Pharmaceutical company Amarin Corp. (Mystic, CN) will present data from its MARINE trial, a Phase III study investigating omega-3 drug AMR101 as a treatment for very high triglycerides.

Pharmaceutical company Amarin Corp. (Mystic, CN) will present data from its MARINE trial, a Phase III study investigating omega-3 drug AMR101 as a treatment for very high triglycerides. The presentation will take place at the National Lipid Association’s 2011 annual scientific sessions in New York City on May 19-22.

The company says that, as previously reported, the MARINE trial met its primary endpoint of percent change in triglyceride levels from baseline to week 12, for both the 2- and 4-g dose groups. It also exhibited no statistically significant increase in low-density lipoprotein cholesterol and a safety profile “similar to placebo.” AMR101 is described as a pure eicosapentaenoic acid (EPA) omega-3 fatty acid.